About Glycosan
Glycosan is a company based in Alameda (United States) founded in 2006 was acquired by Lineage Cell Therapeutics in February 2011. Glycosan has raised $950 thousand across 5 funding rounds from investors including Lineage Cell Therapeutics and HHS. Glycosan operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Alameda, United States
-
Sectors
HealthcareChemicals & Materials
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$950 K (USD)
in 5 rounds
-
Latest Funding Round
$625 K (USD), Seed
May 13, 2010
-
Investors
Lineage Cell Therapeutics
& 1 more
-
Employee Count
Not available
-
Acquired by
Lineage Cell Therapeutics
(Feb 14, 2011)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Glycosan
Glycosan has successfully raised a total of $950K across 5 strategic funding rounds. The most recent funding activity was a Seed round of $625 thousand completed in May 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Glycosan
Glycosan has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Lineage Cell Therapeutics and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Lineage Cell Therapeutics is focused on developing allogeneic cell therapies.
|
Locked | Locked | Locked |
Investor details for Glycosan
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Glycosan
Investment portfolio details for Glycosan
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Glycosan
Detailed financials for Glycosan
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Glycosan Comparisons
Peer comparison for Glycosan
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Glycosan
Glycosan operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Glycosan
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Glycosan
Complete news archive for Glycosan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Glycosan
Glycosan was founded in 2006 and raised its 1st funding round 3 years after it was founded.
Glycosan is headquartered in Alameda, United States. It is registered at Alameda, California, United States.
Glycosan is a funded company, having raised a total of $950K across 5 funding rounds to date.
Glycosan was founded in 2006 in Alameda, United States, focusing on biotechnology for regenerative medicine and tissue engineering. Biocompatible hydrogels, including the proprietary Extracel technology, are created to support stem cell growth and differentiation. These materials serve as implantable, resorbable matrices. The company was acquired by BioTime in February 2011, integrating its operations into broader stem cell research efforts.
Glycosan's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Glycosan has 2 investors. Key investors include Lineage Cell Therapeutics, and HHS.